// App-Quantinova.ai

254 : Impact of secukinumab treatment on psoriatic arthritis patients with or without enthesitis at baseline: pooled data from FUTURE 2 AND FUTURE 3 Phase 3 studies

Researchers

Presenter

  • Iain B McInnes

Principal Investigators

  • Johan K Wallman

  • Georg Schett

  • Erhard Quebe-Fehling

  • Lawrence Rasouliyan

  • Luminita Pricop

  • Andreas E Fasth

  • Corine Gaillez

Medical Centers

  • Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK

  • Department of clinical sciences - Rheumatology, Lund University, Lund, Sweden

  • Department of Internal Medicine , Rheumatology & Immunology, University of Erlangen-Nuremberg, Erlangen, Germany

  • Global Medical Affairs Biostatistics in Global Drug Development, Novartis Pharma AG, Basel, SWITZERLAND

  • Biostatistics, RTI Health Solutions, Barcelona, Spain,

  • Immunology and Dermatology Franchise, Novartis Pharma AG, East Hanover, NJ

  • Novartis Nordics Medical Affairs, Novartis Sverige AB, Täby, SWEDEN

  • Novartis Global Medical Affairs department, Novartis Pharma AG, Basel, SWITZERLAND

Locations

  • United Kingdom

  • Sweden

  • Germany

  • Switzerland

  • Spain

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

Biomarkers

  • N/A

Drug/Treatment

  • secukinumab

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • III

Study Id's

  • NCT01752634

  • NCT01989468

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved